Evidence map›Paper›PMID 34471997›Full record

ReviewHeart failure reviews2022

Clinical management of amyloid cardiomyopathy.

Morris M Kim, Clinton M Kolseth, Dayna Carlson, Ahmad Masri

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Morris M KimCenter for Amyloidosis, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.ORCID 0000-0002-8621-1911
Clinton M KolsethCenter for Amyloidosis, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
Dayna CarlsonCenter for Amyloidosis, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
Ahmad MasriCenter for Amyloidosis, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA. masria@ohsu.edu.
Oregon Health & Science University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical heart failure, restrictive cardiomyopathy, and arrhythmias are hallmark features of amyloid cardiomyopathy. In contrast to the advancements in targeted therapies, there is a general lack of evidence-based practice guidelines for clinical management of amyloid cardiomyopathy. In this review, we review the role of routine medical therapy in amyloid cardiomyopathy, from heart failure management to orthostatic hypotension, atrial arrhythmias, thromboembolic complications, and prevention of sudden death. We conclude by discussing approaches to patients with end-stage disease.

Indexed as

AmyloidosisCardiomyopathiesHeart FailureArrhythmias, CardiacHumansAmyloidosisAtrial fibrillationHeart failureOrthostatic hypotensionRestrictive cardiomyopathySudden cardiac death

Identifiers

PMID34471997
OpenAlexW3197151796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.